Literature DB >> 9173687

[Helicobacter pylori: pretherapeutic resistance status in Germany (Ruhr area)].

B Tillenburg1, S Siehoff, T Becker, U Peitz, G Börsch, J Labenz.   

Abstract

BASIC PROBLEM AND OBJECTIVE OF STUDY: The situation of pretherapeutical antimicrobial drug resistance of Helicobacter pylori has therapeutical implications. For this reason the present study was designed to evaluate the frequency of resistance in Germany.
MATERIAL AND METHODS: A total of 201 H. pylori isolates cultured on the basis of biopsies taken by routine gastroscopies were tested for resistance by E-test. The antibiotics examined were amoxicillin, tetracycline, clarithromycin and metronidazole. For further analysis the last 101 patients were asked for demographical and clinical data that were evaluated for a correlation with metronidazole resistance.
RESULTS: Pretherapeutical resistance against amoxicillin and tetracycline was not detected. The rate of drug resistance against clarithromycin came to 3% and against metronidazole to 29%. There was a higher incidence of metronidazole resistance in female patients (Odds ratio 1.71; p = n.s.). Reliable predictors for metronidazole resistance, however, could not be identified.
CONCLUSIONS: About 30% of H. pylori isolates are pretherapeutically resistant to metronidazole. Resistance to clarithromycin is still rare, but further monitoring remains necessary to detect changes in the community.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9173687

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  3 in total

1.  Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci.

Authors:  Daiva Dailidiene; M Teresita Bertoli; Jolanta Miciuleviciene; Asish K Mukhopadhyay; Giedrius Dailide; Mario Alberto Pascasio; Limas Kupcinskas; Douglas E Berg
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 2.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

3.  Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany.

Authors:  K Wolle; M Nilius; A Leodolter; W A Müller; P Malfertheiner; W König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-07       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.